Supporting Alzheimer’s disease diagnosis with Artificial Intelligence
MINT-AD
Multimodal Interpretable Transformer for Alzheimer's Disease.
Empower Clinical Excellence with Less Effort
MINT-AD use decades of international research in genomics, clinical practice, and cognitive science into a seamless intelligence platform.
Patients
Families
MINT-AD brings world-class AI risk prediction and decision support directly into the hands of:
Patients and Families:
Accelerated and transparent diagnostics, enabling earlier interventions.
Physicians:
Accurate, individualized insights, even in regions with limited medical technology.
Researchers:
Accelerated and transparent diagnostics, enabling earlier interventions.
Advanced Data. Broader Insights:
MINT-AD provides interpretable predictions, revealing which variables drive each risk score and why.
Demographic
Location
Age
Gender
Living
Coditions
& other
socioeconomic
factors
Clinical History
Family History
Over 390
Medical Variables
Brain images
Magnetic
Resonance Imaging
PET
Computed
Tomography Scans
Omics Data
Genetics
Epigenetics
Specific
Biomarkers
Cognitive tests
Neuropsychological
Evaluations
Memory
Language
Attention
Why to develop
MINT-AD
Reduces diagnostic delays in underserved areas where there’s a lack of resources and equipment for diagnosis.
Identify new combinations of risk factors across all the data modalities.
Identify new combinations of risk factors across all the data modalities.
Empowering Better Outcomes Through
Data-Driven Alzheimer’s Solutions
Reduce diagnostic
Uncertainty with interpretable, science-backed outputs
Smart Recommendations, Personalized Outcomes
Reach underserved communities: Efficient diagnosis without the need for advanced infrastructure
Integrate Effortlessly
Uncover new risk factors: Multidimensional data reveals novel combinations of social, genetic, and lifestyle determinants
Reduce inequality
Designed for high accuracy where false negatives are common
Meet the leader behind MINT-AD
Other projects you may like
IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette’s Syndrome
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50.”
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
